Details

Autor(en) / Beteiligte

• Fujiwara, Yu
• Karol, Alexander B.
• Joshi, Himanshu
• Reford, Emma
• Izadmehr, Sudeh
• Doroshow, Deborah B.
• Galsky, Matthew D.

Titel

C-reactive protein (CRP) as a prognostic biomarker in patients with urothelial carcinoma: A systematic review and meta-analysis

Ist Teil von

• Critical reviews in oncology/hematology, 2024-05, Vol.197, p.104352-104352, Article 104352

Ort / Verlag

Netherlands: Elsevier B.V

Erscheinungsjahr

2024

Quelle

Access via ScienceDirect (Elsevier)

Beschreibungen/Notizen

• C-reactive protein (CRP) may reflect a pro-inflammatory tumor microenvironment and could represent a biomarker to select patients with urothelial carcinoma more likely to benefit from therapies directed at modulating tumor-promoting inflammation. We performed a systematic review to evaluate survival outcomes based on pre-treatment CRP values in urothelial carcinoma. The hazard ratios (HRs) of survival such as overall survival (OS) and progression-free survival (PFS) between groups with high versus low CRP values were pooled by the random-effect model meta-analyses. Overall, 28 studies comprising 6789 patients were identified for meta-analyses. High CRP levels were associated with shorter OS (HR=1.96 [95% CI: 1.64–2.33], p < 0.01), particularly in advanced disease treated with immune checkpoint blockade (ICB, HR=1.78 [1.47–2.15], p < 0.01). Similar findings were observed in ICB-treated patients with PFS. These findings suggest that CRP could be an attractive biomarker to select patients with urothelial carcinoma for strategies seeking to modulate tumor-promoting inflammation. [Display omitted] •C-reactive protein (CRP) is an acute phase reactant may reflect a pro-inflammatory tumor microenvironment.•A systematic review found 28 studies reporting clinical outcomes based on pre-treatment CRP values in urothelial carcinoma.•High CRP levels were associated with shorter overall survival in patients with urothelial carcinoma.•This association was particularly seen in advanced urothelial carcinoma treated with immune checkpoint blockade.•CRP could be a biomarker to select patients for strategies seeking to modulate tumor-promoting inflammation.